Page last updated: 2024-11-01

ondansetron and Leukemia, Erythroblastic, Acute

ondansetron has been researched along with Leukemia, Erythroblastic, Acute in 1 studies

Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Leukemia, Erythroblastic, Acute: A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.

Research Excerpts

ExcerptRelevanceReference
"Human hepatoma cells (HepG2) were cultured for 7 days in modified Earle's medium in order to induce their drug metabolising (primarily mixed function oxidase) enzymes."1.28Development of a co-culture system with induced HepG2 cells and K562 cells for examining drug metabolism in vitro. Studies with cyclophosphamide, ondansetron and cisplatin. ( Cambridge, G; Hall, TJ; James, PR, 1991)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hall, TJ1
Cambridge, G1
James, PR1

Other Studies

1 other study available for ondansetron and Leukemia, Erythroblastic, Acute

ArticleYear
Development of a co-culture system with induced HepG2 cells and K562 cells for examining drug metabolism in vitro. Studies with cyclophosphamide, ondansetron and cisplatin.
    Research communications in chemical pathology and pharmacology, 1991, Volume: 72, Issue:2

    Topics: Antiemetics; Carcinoma, Hepatocellular; Cell Division; Cell Survival; Cisplatin; Cyclophosphamide; D

1991